---
document_datetime: 2026-02-05 10:18:52
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/prevenar-13-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: prevenar-13-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.19073
conversion_datetime: 2026-02-09 22:03:58.410808
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Prevenar 13

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type II /  | This was an application for a group of | 15/01/2026                          |                                             | Annex II                         | Annex II.A has been updated to reflect the correct |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000309455   | variations.   | names of the biological active substance manufacturers sites.   |
|---------------------|---------------|-----------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted                                                                                                                                                                                                                                         |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000317316 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.f Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products - Accepted B.II.c.4 Change in synthesis or recovery of a nonpharmacopoeial excipient (when described in the dossier) or a novel excipient - B.II.c.4.a Minor change in synthesis or recovery of a nonpharmacopoeial excipient | 14/01/2026 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000300819 | This was an application for a group of variations. B.II.e.4 Change in shape or dimensions of the container or closure (immediate packaging) - B.II.e.4.c Sterile medicinal products - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.z Change in supplier of sterilised primary container components, which are to be used in the aseptic manufacture of medicinal products - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.z Change in supplier of sterilised primary container components, which are to be used in the aseptic manufacture of medicinal products - Accepted | 16/10/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | components or devices (when mentioned in the dossier) - B.II.e.7.b Replacement or addition of a supplier - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |                       |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------|
| Variation type IB / EMA/VR/0000254585 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where | 24/04/2025 | SmPC, Annex II and PL |

<div style=\"page-break-after: always\"></div>

|                                       | · Type IB (C.I.z) - Update of Product Information to include updated wording for Polysorbate 80 in Prevenar 13 SmPC and Package Leaflet. · Type IA (A.4) - Change in the legal entity name and address of the currently registered manufacturer of active substance and the currently registered master cell bank storage site Pfizer Ireland Pharmaceuticals, Grange Castle. · Type IA (A.5(b)) - Change in the legal entity name and address of the currently registered manufacturer of finished product, Pfizer Ireland Pharmaceuticals, Grange Castle. In addition, the MAH took the opportunity to align the PI to the latest QRD template 10.4 and to update the contact details of the Irish local representative.   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000254759 | This was an application for a group of variations. B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                               | 25/03/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|